(Yicai) April 8 -- More than half of pharmaceutical companies listed in the Chinese mainland have reported an increase in their net profit for last year, mainly thanks to the commercialization of innovative drugs and licensing-out deals.

Sixty out of the 112 Chinese mainland-listed drugmakers that had already released their 2025 financial statements as of April 6 saw their net profit widen last year, according to incomplete statistics.

Hengrui Pharmaceuticals logged CNY7.7 billion (USD1.1 billion) in net profit in 2025, up nearly 22 percent from the year before. Revenue rose 13 percent to CNY31.6 billion (USD4.6 billion) in the period, as revenue from innovative drugs and licensing-out deals both surged 26 percent to CNY16.3 billion and CNY3.4 billion, respectively.

This year, Hengrui Pharma expects its sales revenue from innovative drugs to climb over 30 percent from last year.

InnoCare Pharma posted its first annual profit of CNY642 million (USD94 million) in 2025, with operating revenue up 135 percent to nearly CNY2.4 billion from the year before, thanks to the income from licensing-out deals.

Fosun Pharmaceutical Group reported a 22 percent jump in net profit to CNY3.4 billion last year from 2024. Its operating revenue inched up 1.5 percent to CNY41.7 billion, with revenue from innovative drugs accounting for over 33 percent of the company’s total pharmaceutical revenue, and revenue from overseas businesses making up about 31 percent of its overall operating revenue.

Chunlizhengda Medical Instruments saw its net profit skyrocket 118 percent in 2025 from the year before, with revenue up nearly 30 percent. The firm attributed the strong performance to the stable supply of products included in China’s centralized procurement and the in-depth expansion in the international market.

Weigao Orthopedic Device reported a 20 percent leap in net profit to CNY268.6 million last year from 2024, and a 4.8 percent rise to CNY1.5 billion in operating revenue. The company said it benefited from the smooth implementation of volume-based procurement and the continuous increase in the market share of Chinese brands.

Firms engaged in pharmaceutical research and development outsourcing, such as WuXi AppTec, Porton Pharma Solutions, and Tigermed Consulting, said their profit doubled last year. The former attributed the results to the continuous deepening of its ‘contract research, development, and manufacturing organization’ model and the improvement of production efficiency in clinical commercialization projects.

Innovative R&D and industrial upgrading have become the core focuses of the pharmaceutical industry, experts believe. The health service model is accelerating its reconstruction, with the prominent trend of integration between online and offline services, as well as personalized services.

Consumer demands are evolving rapidly towards diversification, customization, and hi-tech. The competitive edge of enterprises with strong innovative R&D and overseas layout will continue to expand, while those with weak R&D capabilities will face further operational pressure.

Editor: Futura Costaglione